Next Phase Newsletter

An early stage healthcare focused venture capital firm headquartered in the East Coast USA invests in Pre-Seed, Seed and Series A rounds across all four life science sectors. The firm has a current fund of $50M that they are actively raising and investing out of. The typical check size ranges from $100K – $1.5M in the form of priced rounds, equity, SAFEs or convertible notes. The firm invests globally, with a focus on helping companies outside of the US get into the US market.

The firm seeks to make investments in all four life science sectors, and is agnostic to subsector and indication. The firm is looking to provide start-ups with capital as well as advisory and strategic input when needed. The firm is open to pre-clinical companies and is open to all three classes of medical devices.

The firm is open to all types of management teams including first time entrepreneurs and underrepresented groups. The firm likes to typically lead investments, and will seek a board seat, but is also open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital company was founded in 2007 and based in Durham, North Carolina with additional office in Orlando, Florida. The firm has approximately $38 million in total assets under management. The firm seeks to make equity investments in 2 to 3 companies in the next 6 to 9 months. The average first investment in a company is $0.1 million to $ 0.75 million, though it can invest up to $ 1.5 million, depending on the opportunity. The firm prefers to invest in seed and early- stage companies located in the Southeast and Mid-Atlantic regions of the US with a focus in the states of North Carolina and Florida.

The firm is currently looking for new investment opportunities in Medical Technology and Healthcare IT spaces. The firm is most interested in companies producing medical devices and software. The firm is very opportunistic in terms of medical devices, and it would consider companies operating within any subsector of medical technology. The firm generally makes investments in pre-clinical and prototype stages within medical technology sector.

The firm will consider pre-revenue companies and make initial investments in companies with no revenues. The firm prefers to invest in technologies that are disruptive to existing markets or enable entirely new ones. The firm will not consider any biotechnology and pharmaceutical companies, and additionally would not be interested in growth companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Based in San Francisco, CA, and has an additional office in Japan, a venture capital firm is investing from a new fund that closed in 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions. It has invested thus far in some well-known companies.

The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital firm based in Southern California is actively making early-stage investments in all sectors of healthcare. The firm is currently investing from their first fund, through which the firm will invest in 25-40 companies over the next 3-5 years. To date, the firm’s current portfolio includes over 25 companies. The firm’s typical size of initial investment is $100-500K in the form of equity, convertible note, among other monetary vehicles. The firm focuses on Seed to Series A-stage companies that are based in Southern California, but opportunistically invest across all of USA and the world.

The firm invests in medical device, diagnostics, and digital health companies, but will generally not invest in therapeutics or biopharmaceuticals. The firm is opportunistic and will consider all promising technologies within the aforementioned sectors.

The firm generally invests in companies with a pre-money valuation less than $10M, but is capable of participating in investments in larger companies. The firm likes to companies within 6 months of FDA clearance or approval, or revenue generation. The firm is open to working with small/inexperienced management teams and is agnostic with regards to management team requirements. The firm is an active investor who selectively serve on boards, and actively engages their LPs who have healthcare subject matter expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The company is Canada’s largest diagnostic lab and is the leading diagnostic testing facility for communities in Ontario and BC. The company does 120 million diagnostic tests a year in centralized labs and 450+ offices and patient service centers. The firm has made a number of acquisitions in the last 10 years, and consolidated lab testing by acquiring the largest competitive lab in Ontario and the only competitive lab in BC. The firm is looking solely for long term strategic partnerships with organizations that have technology in point of care testing and novel diagnostic testing as well as technology platforms. The company looks globally for opportunities.

The company is looking for strategic partnerships in both the medical device and diagnostic sectors. The firms main focus is point of care technologies, rapid testing, cardiovascular, wearables and biometrics, and the firm is open to all indications. The company also looks to women and men’s health, as well as novel mental health and brain related technologies. The firm is open to pre-clinical companies.

The company looks for management teams with deep subject matter expertise within their field and a strong track record. The firm is open to both co-investing or leading an investment, where they will seek board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is Healthcare focused fund, headquartered in Shanghai and has presence in US and Europe. The fund has strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, they have strong preference to lead investments and play active contribute to the success in their portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, CNS and hearing related opportunities. Panacea Venture is otherwise agnostic in regards to specific disease indications and is willing to look at all early-stage opportunities, however, diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies. Outside of the board requirement, the firm is looking for strong management team with passion and capability in advancing the company’s technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture builder founded in 2016 and is headquartered in the United Kingdom. The firm seeks to build new ventures from scratch, generating innovation in novel science and technology from the earliest stages of development. Currently, the firm is focused on 4 main pillars: energy, agriculture, curative therapeutics, and computation. The firm invests pre-seed/seed capital into the companies they build. The firm will consider global opportunities.

Within life sciences, the firm is indication agnostic and has worked in areas including cystic fibrosis, oncology, neurodegeneration and microbiome. The firm has partnered with groups such as the Cystic Fibrosis Foundation and Cancer Research UK to devise new therapeutic approaches in their key focus areas. The firm has a strong interest in cell & gene therapy and synthetic biology, but is open to considering all other modalities – the firm has also launched companies that work on a more traditional approach. In terms of stage of development, the firm invests in the companies it builds at formation stage and is open to working together with other organizations to undertake company creation and support proof-of-concept data generation. The firm generally does not currently build, or invest in, medical devices, diagnostics, or digital health companies.

As a venture builder, the firm does not have strict requirements or expectations on company operations or management team. The firm has generally built companies in the UK. That said, the firm has worked with scientists all across the globe to build its companies, and their portfolio also includes companies in other geographies such as the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.